Tag: nasdaq:ears

October 11, 2019

Auris Medical Releases Results from MAP US2 Open-Label Extension Study

The company announced results from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and somnolence.
September 11, 2019

Auris Medical Receives Notice of Allowance for US and European Patent Applications

Auris Medical Holding (NASDAQ:EARS) has announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance...
May 15, 2019

Auris Medical Closes Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD

Auris Medical Holding (NASDAQ:EARS) has announced it has closed the purchase of two US patents for use of betahistine to...
March 29, 2019

Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study

Auris Medical (NASDAQ:EARS) has announced the first cohort of subjects have been randomized in its Phase 1b proof-of-concpet trial of...
March 11, 2019

Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal

Auris Medical Holding AG (NASDAQ:EARS) has announced the publication of an article that details the outcomes from the HEALOS Phase...
November 20, 2018

Auris Medical Shares Positive FDA Meeting Results

The regulatory agency supports Auris’ plan to conduct multiple doses of AM-201 in a Phase 1 trial with healthy volunteers....
November 20, 2018

Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program

Auris Medical (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental...